# Do-Youn Oh

Source: https://onco.cc/people/oh-do-youn/  
OnCo record `oh-do-youn` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Principal investigator of TOPAZ-1, the trial that added immunotherapy to first-line chemotherapy for bile duct cancer.

## Summary

Do-Youn Oh is Professor of Internal Medicine at Seoul National University Hospital, specialising in gastrointestinal and hepatobiliary oncology. She was principal investigator of TOPAZ-1, the trial that added the immunotherapy durvalumab to first-line gemcitabine plus cisplatin for advanced biliary tract cancer, the first phase 3 in more than a decade to improve outcomes in that disease. Her publications include the TOPAZ-1 report on durvalumab plus gemcitabine and cisplatin. She runs pancreatic and biliary clinical trials at Seoul National University Hospital, with interests in immunotherapy for biliary tract cancer and pancreatic cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Internal Medicine; gastrointestinal and hepatobiliary oncology
- Specialisms: Biliary tract cancer; Pancreatic cancer; Immunotherapy; Clinical trials

## Sources

- Seoul National University Hospital: https://www.snuh.org
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Oh%20DY%5BAuthor%5D%20biliary%20tract%20cancer%20Seoul%20National%20University

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Gemcitabine + cisplatin](https://onco.cc/drugs/gemcitabine-cisplatin/)
- institutions: [Seoul National University Hospital](https://onco.cc/institutions/snuh/)
- trials: [TOPAZ-1](https://onco.cc/trials/topaz-1/)
- journals: [NEJM Evidence](https://onco.cc/journals/nejm-evidence/)
- key papers: [Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02](https://onco.cc/key-papers/paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026/), [NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours](https://onco.cc/key-papers/paper-netter-2-lancet-2024/), [Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study](https://onco.cc/key-papers/paper-harding-lancet-oncol/)

---
JSON: https://onco.cc/api/v1/entities/oh-do-youn.json